Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Blood Coagulation Disorders, Inherited

ClinicalTrials.gov lists 1,121 trials for Blood Coagulation Disorders, Inherited or a narrower condition beneath it. Novo Nordisk A/S has the most among industry and government lead sponsors, with 84.

MeSH D025861 Hemic and Lymphatic Diseases C15 C16 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 103 Phase 1/2 Phase 1/2 55 Phase 2 Phase 2 71 Phase 2/3 Phase 2/3 23 Phase 3 Phase 3 211 Phase 4 Phase 4 86 Not applicable Not applicable 146 Observational Observational 423 Phase 1 Phase 1 103 Phase 1/2 Phase 1/2 55 Phase 2 Phase 2 71 Phase 2/3 Phase 2/3 23 Phase 3 Phase 3 211 Phase 4 Phase 4 86 Not applicable Not applicable 146 Observational Observational 423

Trials per phase

1 more section with rows

20 of the 1,121 trials are tagged with Blood Coagulation Disorders, Inherited itself; the rest are tagged with a narrower condition beneath it.

Get the Blood Coagulation Disorders, Inherited report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Blood Coagulation Disorders, Inherited trials start? (35)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 5 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 71

1990: 1 trials (Observational 1) 1992: 1 trials (Phase 1/2 1) 1993: 1 trials (Phase 1 1) 1994: 1 trials (Not applicable 1) 1995: 3 trials (Observational 3) 1997: 3 trials (Phase 4 1, Phase 3 2) 1998: 1 trials (Observational 1) 1999: 2 trials (Observational 2) 2000: 5 trials (Observational 1, Not applicable 3, Phase 3 1) 2001: 9 trials (Observational 1, Not applicable 1, Phase 4 2, Phase 3 3, Phase 2/3 2) 2002: 12 trials (Observational 6, Phase 3 3, Phase 2/3 1, Phase 2 1, Phase 1 1) 2003: 9 trials (Observational 2, Not applicable 1, Phase 4 3, Phase 3 2, Phase 2/3 1) 2004: 12 trials (Observational 6, Phase 3 3, Phase 2/3 1, Phase 2 1, Phase 1/2 1) 2005: 25 trials (Observational 7, Not applicable 3, Phase 4 3, Phase 3 5, Phase 2 4, Phase 1 3) 2006: 15 trials (Observational 2, Not applicable 2, Phase 4 5, Phase 3 3, Phase 2/3 1, Phase 2 1, Phase 1 1) 2007: 18 trials (Observational 7, Phase 4 2, Phase 3 3, Phase 2 4, Phase 1/2 2) 2008: 30 trials (Observational 11, Phase 4 5, Phase 3 3, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 4) 2009: 45 trials (Observational 12, Not applicable 3, Phase 4 5, Phase 3 11, Phase 2/3 2, Phase 2 5, Phase 1 7) 2010: 37 trials (Observational 9, Not applicable 3, Phase 4 3, Phase 3 9, Phase 2/3 1, Phase 2 4, Phase 1/2 1, Phase 1 7) 2011: 40 trials (Observational 12, Not applicable 3, Phase 4 1, Phase 3 13, Phase 2/3 1, Phase 1/2 4, Phase 1 6) 2012: 42 trials (Observational 10, Not applicable 7, Phase 4 1, Phase 3 10, Phase 2/3 4, Phase 2 1, Phase 1 9) 2013: 26 trials (Observational 7, Phase 4 3, Phase 3 10, Phase 2/3 1, Phase 2 2, Phase 1/2 2, Phase 1 1) 2014: 55 trials (Observational 22, Not applicable 6, Phase 4 3, Phase 3 11, Phase 2/3 1, Phase 2 2, Phase 1/2 3, Phase 1 7) 2015: 71 trials (Observational 34, Not applicable 9, Phase 4 6, Phase 3 8, Phase 2 3, Phase 1/2 4, Phase 1 7) 2016: 45 trials (Observational 21, Not applicable 6, Phase 4 3, Phase 3 8, Phase 2 1, Phase 1/2 1, Phase 1 5) 2017: 51 trials (Observational 20, Not applicable 5, Phase 4 3, Phase 3 8, Phase 2 6, Phase 1/2 4, Phase 1 5) 2018: 65 trials (Observational 28, Not applicable 10, Phase 4 4, Phase 3 11, Phase 2 4, Phase 1/2 5, Phase 1 3) 2019: 60 trials (Observational 28, Not applicable 5, Phase 4 3, Phase 3 10, Phase 2 6, Phase 1/2 3, Phase 1 5) 2020: 66 trials (Observational 31, Not applicable 14, Phase 4 5, Phase 3 8, Phase 2/3 1, Phase 2 2, Phase 1/2 3, Phase 1 2) 2021: 68 trials (Observational 23, Not applicable 15, Phase 4 5, Phase 3 12, Phase 2/3 1, Phase 2 1, Phase 1/2 3, Phase 1 8) 2022: 51 trials (Observational 18, Not applicable 7, Phase 4 7, Phase 3 6, Phase 2 2, Phase 1/2 5, Phase 1 6) 2023: 59 trials (Observational 21, Not applicable 11, Phase 4 4, Phase 3 9, Phase 2/3 1, Phase 2 4, Phase 1/2 6, Phase 1 3) 2024: 67 trials (Observational 30, Not applicable 12, Phase 4 2, Phase 3 12, Phase 2/3 1, Phase 2 2, Phase 1/2 3, Phase 1 5) 2025: 50 trials (Observational 21, Not applicable 5, Phase 4 3, Phase 3 10, Phase 2/3 2, Phase 2 4, Phase 1/2 1, Phase 1 4)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 54
2025 50
2024 67
2023 59
2022 51
2021 68
2020 66
2019 60
2018 65
2017 51

Showing 10 of 35 earlier years.

Start your 14-day trial Email me all 35 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 65 trials starting in 2026 and about 57 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 70 trials still running at the 2026-10-09 snapshot; registered median of 23 months across 732 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Blood Coagulation Disorders, Inherited trials in? (9)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 103
Phase 1/2 55
Phase 2 71
Phase 2/3 23
Phase 3 211
Phase 4 86
Not applicable 146
Observational 423
Expanded access 3

How many Blood Coagulation Disorders, Inherited trials are recruiting? (12)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 39
Recruiting 116
Enrolling by invitation 16
Active, not recruiting 47
Available 1

Showing 5 of 12 statuses.

Start your 14-day trial Email me all 12 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Blood Coagulation Disorders, Inherited trials? (12)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Novo Nordisk A/S 84
Baxalta now part of Shire 59
Bayer 56
Pfizer 44
CSL Behring 40

Showing 5 of 12 sponsors.

Start your 14-day trial Email me all 12 sponsors as a PDF

Which drugs are being tested for Blood Coagulation Disorders, Inherited? (13)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
ADVATE 38
Emicizumab 27
activated recombinant human factor VII 23
Moroctocog alfa 19
BENEFIX 18

Showing 5 of 13 drugs.

Start your 14-day trial Email me all 13 drugs as a PDF

Interventions as named in the registry (2)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Recombinant Factor VIII (50 IU/kg) 19
No treatment given 11

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Blood Coagulation Disorders, Inherited trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Factor VIII inhibition 150 18
Haemarthrosis 82 33
Fall 77 27
Head injury 60 24
Haemophilic arthropathy 58 15

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Blood Coagulation Disorders, Inherited? (23)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Genomic testing for bleeding disorders (GT4BD): protocol for a randomised controlled trial evaluating the introduction of whole genome sequencing early in the diagnostic pathway for patients with inherited bleeding disorders as compared with standard of care. BMJ open 2025 Yes
Genomic landscape of patients with germline RUNX1 variants and familial platelet disorder with myeloid malignancy. Blood advances 2024 Yes
Genetic screening of children with suspected inherited bleeding disorders. Haemophilia : the official journal of the World Federation of Hemophilia 2020 Yes
Genome-Wide Association Transethnic Meta-Analyses Identifies Novel Associations Regulating Coagulation Factor VIII and von Willebrand Factor Plasma Levels. Circulation 2019 Yes
Elevated thrombin generation in patients with congenital disorder of glycosylation and combined coagulation factor deficiencies. Journal of thrombosis and haemostasis : JTH 2019 Yes

Showing 5 of 23 publications.

Start your 14-day trial Email me all 23 publications as a PDF

Sub-conditions in MeSH (17)

MeSH descendants one level down with at least one trial, most trials first.

+7 more sub-conditions

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages